Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease.

Area of Science:

• Endocrinology
• Immunology
• Pediatric Medicine

Background:

• Graves' hyperthyroidism in young people has low remission rates (<25%) with standard antithyroid drugs (ATD) alone after two years.
• Novel therapeutic strategies are needed to improve long-term remission in pediatric Graves' disease.

Purpose of the Study:

• To investigate if rituximab (RTX), a B-lymphocyte depletor, can enhance remission rates when used with a short course of ATD in adolescents and young adults with Graves' hyperthyroidism.

Main Methods:

• An open-label, phase 2, single-arm trial involving 27 participants (ages 12-20) with Graves' hyperthyroidism.
• Participants received RTX (500 mg) and 12 months of ATD, with treatment cessation at 12 months and assessment at 24 months.
• Remission was defined by normalized thyroid function tests and absence of further ATD use, surgery, or radioiodine treatment.

Main Results:

• A total of 13 out of 27 participants (48%) achieved remission at 24 months, exceeding the study's target remission rate.
• No serious side effects were reported. Lower daily carbimazole doses were used by month 12 in most participants.
• Reduced B-lymphocyte counts at 28 weeks correlated with a higher likelihood of remission.

Conclusions:

• Adjuvant rituximab (RTX) with a 12-month antithyroid drug (ATD) course appears to increase remission rates in young individuals with Graves' hyperthyroidism.
• Further investigation via a randomized controlled trial is recommended to confirm the efficacy of RTX in this population.